Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Sristee Shrestha Prajapati

Bhaktapur Cancer Hospital, Nepal

Title: Outcome of staging laparotomy in ovarian mass in limited resource centre

Biography

Biography: Sristee Shrestha Prajapati

Abstract

Background: Ovarian cancer is the second most common gynecologic cancer in women and the leading cause of death caused
by gynaecologic malignancy. Th e clinical diagnosis of ovarian malignancy is problematic, given the nonspecifi c nature of
presentation and the diffi culty in obtaining a histological diagnosis prior to defi nite treatment. Surgery plays a fundamental
role in treating this challenging disease. Goals of primary surgery for ovarian cancer are to establish diagnosis, proper staging,
and determination of prognosis and optimal cytoreduction of gross disease before chemotherapy for improved outcome.
Objectives: Th e objective of this study is to evaluate the benefi ts and risks of staging laparotomy in diagnosis of ovarian
tumor; to correlate CA 125 with benign and malignant ovarian tumor and to determine the age distribution in the benign and
malignant ovarian tumor.
Design: Retrospective descriptive study
Methods: Th e case records of patient presenting with ovarian masses that underwent staging laparotomy between 2016 May
to 2017 September at Bhaktapur Cancer Hospital were analyzed. Demographic and clinical data were reviewed. Correlation of
CA 125 in both malignant and benign cases was studied.
Results: 44 patients with ovarian masses undergoing staging laparotomy were included with age variation from 19 to 88. Th e
mean age was 52 years. 15 (34%) were malignant cases, 2 (4.5%) cases had borderline tumor and remaining 27 (61%) benign.
Th e mean age group in malignant cases, borderline cases and benign cases were 45, 64 and 55 years respectively. P value is
signifi cant (P=0.0234). Th is study shows mean value of CA 125 as 212.8 in malignant cases, 9.8 and 80.49 in borderline tumor
and benign cases respectively. P value signifi cant (p=0.0315). Out of 15 malignant cases, 8(53.3%) cases were in stage Ia,
1(7%) case in stage Ic and 6(40%) cases were in stage IIIc. Among malignant cases 4 out of 15 had lymphovascular invasion,
in which 2 out of 4 had omental metastasis and 2 out of 4 had lymph node metastasis. All these 4 cases were stage IIIc. Th e
CA 125 level was signifi cantly high in 4 out of 6 malignant cases ranging from 400 to 1000 units/ml with stage IIIc whereas 1
case with sarcoma had 20 units/ml, and another with mature cystic teratoma with squamous cell carcinoma had 24.4 units/ml.
In 27 benign cases, 1 had raised CA 125 level upto 862 units/ml with diagnosis of abdominal tuberculosis with mature cystic
teratoma whereas 3 cases of endometriosis had CA 125 level ranging from 150-200 units/ml.
Conclusion: Detection of pelvic mass with raised CA 125 level raises suspicion for ovarian malignancy, but there are various
benign pelvic conditions that are associated with raised CA 125 level. Th is is more important in the Nepalese subcontinent
where genital tuberculosis and endometriosis is common as seen in our case series where 11.11 % of cases of benign pelvic
masses with raised CA 125 level turned out to be endometrioma. However, 26.66% of malignant cases had signifi cantly raised
CA 125 level. Th e use of frozen section service for immediate intra-operative reporting is highly attractive for the gynecologic
oncology surgeon. It allows for a single optimal operative staging procedure where indicated and, likewise, for a non-staging
procedure if not required.